Drug intelligence / Profile preview

MB-IMP

Development stage: Phase 2
Modality: Small Molecules
Administration: Oral

Overview

MB-IMP is a marijuana-based investigational medical product (IMP) composed of cannabidiol (CBD) and tetrahydrocannabinol (THC) in a 23:1 ratio. It is being investigated as a potential treatment for anxiety in autistic adults. The drug is administered orally in drops and aims to alleviate anxiety symptoms by modulating the endocannabinoid system and other relevant pathways.

Other names: marijuana-based investigation medical product

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on MB-IMP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MB-IMP.

Explore the full profile